Allarity Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALLR Nasdaq 8731 https://allarity.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allarity Therapeutics Inc

6 F-Rated Penny Stocks Not Worth Your Dime - Jan 31st, 2023 12:54 pm
Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders - Jan 20th, 2023 9:01 pm
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date - Dec 1st, 2022 9:25 pm
Allarity Therapeutics Reports Third Quarter 2022 Financial Results - Nov 15th, 2022 9:01 pm
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders - Nov 7th, 2022 11:15 pm
Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform - Oct 18th, 2022 12:00 pm
Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements - Oct 11th, 2022 8:05 pm
Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors - Sep 26th, 2022 10:00 am
Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference - Sep 16th, 2022 10:00 am
ALLR: A Precision Undertaking - Sep 13th, 2022 9:20 am
Allarity Therapeutics Announces Appointment of New Auditor - Sep 12th, 2022 8:10 pm
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) - Aug 26th, 2022 8:30 pm
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies - Aug 2nd, 2022 10:00 am
Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D. - Jul 11th, 2022 11:00 am
Allarity Therapeutics Announces Executive Leadership Transition - Jun 29th, 2022 8:01 pm
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D. - Jun 15th, 2022 1:25 pm
Allarity Therapeutics Reports First Quarter 2022 Financial Results - May 27th, 2022 9:37 pm
Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update - May 18th, 2022 9:30 pm
Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update - May 16th, 2022 11:40 pm
Allarity Therapeutics Provides Update on Dovitinib Program - Mar 15th, 2022 12:32 pm